rs773454367
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_001101362.3(KBTBD13):c.272C>A(p.Pro91Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000166 in 1,521,100 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Consequence
NM_001101362.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
KBTBD13 | NM_001101362.3 | c.272C>A | p.Pro91Gln | missense_variant | 1/1 | ENST00000432196.5 | NP_001094832.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
KBTBD13 | ENST00000432196.5 | c.272C>A | p.Pro91Gln | missense_variant | 1/1 | 6 | NM_001101362.3 | ENSP00000388723.2 |
Frequencies
GnomAD3 genomes AF: 0.000138 AC: 21AN: 151972Hom.: 0 Cov.: 34
GnomAD3 exomes AF: 0.0000588 AC: 7AN: 119004Hom.: 0 AF XY: 0.0000759 AC XY: 5AN XY: 65900
GnomAD4 exome AF: 0.000169 AC: 232AN: 1369128Hom.: 0 Cov.: 57 AF XY: 0.000163 AC XY: 110AN XY: 675698
GnomAD4 genome AF: 0.000138 AC: 21AN: 151972Hom.: 0 Cov.: 34 AF XY: 0.000121 AC XY: 9AN XY: 74272
ClinVar
Submissions by phenotype
KBTBD13-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Nov 29, 2023 | The KBTBD13 c.272C>A variant is predicted to result in the amino acid substitution p.Pro91Gln. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.020% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 12, 2024 | The c.272C>A (p.P91Q) alteration is located in exon 1 (coding exon 1) of the KBTBD13 gene. This alteration results from a C to A substitution at nucleotide position 272, causing the proline (P) at amino acid position 91 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Nemaline myopathy 6 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 29, 2023 | This sequence change replaces proline, which is neutral and non-polar, with glutamine, which is neutral and polar, at codon 91 of the KBTBD13 protein (p.Pro91Gln). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with KBTBD13-related conditions. ClinVar contains an entry for this variant (Variation ID: 577515). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt KBTBD13 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at